Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO			0	Complete if known		
				Application Number	10/589,052; Conf. No. 5470	
INFORMATION DISCLOSURE				Filing Date	September 8, 2008	
STATEMENT BY APPLICANT  (use as many sheets as necessary)			PLICANT	First Named Inventor	Kambiz Shekdar	
			,	Art Unit	1654	
			necessary)	Examiner Name	Amber D. Steele	
Sheet	1	of	2	Attorney Docket Number	002298-0003-101	

			U.S. PATENT I	OCUMENTS				
Examiner Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Releva				
	No. <sup>1</sup>	Number – Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Documents	Passages or Relevant Fi	gures Appear		
		2003/096322	05-22-2003	Giuliano et al.				
		FOR	EIGN PATEN	T DOCUMENTS	•			
Eveminer	Cito	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines,			
Examiner initials*	Cite No. <sup>1</sup>	Country Code <sup>1</sup> – Number <sup>2</sup> - Kind Code <sup>3</sup>			Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>		
		WO 200131059	05-03-2001	Molecular Light Tech Res Ltd.				
		NON PA	TENT LITERA	TURE DOCUMENTS	*	•		
Examiner initials*						76		
		BRAASCH et al., "Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design", Nucleic Acids Research, 30(23): 5160-5167 (2002)						
		GAIT, "Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues", CMLS, Cell. Mol. Life Sci. 60:844-853 (2003)  GOPALAKRISHNAN et al., "siRNA and DNA Transfer to Cultured Cells", Methods in Molecular Biology, 480: 31-52 (2009)						
	HOFFMANN et al., "Expression screening of factors binding to the osteocalcin bone-specific promoter element OC Box I: isolation of a novel osteoblast differentiation-specific factor," J. Cell. Biochem. 80:156-168 (2000)							
	KURRECK, "Antisense technologies: Improvement through novel chemical modifications", Eur. J. Biochem. 270:1628–1644 (2003)  MITCHELL, "Turning the spotlight on cellular imaging", Nature Biotechnology, 19(11): 1013-1017 (2001)							
			STEROVA et al., "Killing the Messenger: Antisense DNA and siRNA", rrent Drug Targets, 5: 683-689 (2004)					
		PESTOV et al., "Genet mammalian cells," Prod						

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450**, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if known		
				Application Number	10/589,052; Conf. No. 5470	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	September 8, 2008	
				First Named Inventor	Kambiz Shekdar	
				Art Unit	1654	
(use as many sheets as necessary)			necessary)	Examiner Name	Amber D. Steele	
Sheet	2	of	2	Attorney Docket Number	002298-0003-101 (CHROMO/003)	

U.S. PATENT DOCUMENTS					
	ROSE, "Optimization of Transfection", Current Protocols in Neuroscience (1997) A.1B.1-A.1B.3				
	STARK et al., "Forward genetics in mammalian cells: function approaches to gene discovery," Human Molecular Genetics 8(10):1925-1938 (1999)				
	ZAMBROWICZ et al., "Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells," Nature 392:608-611 (1998)				
	ZHENG et al., "A system for rapid generation of coat color-tagged knockouts and defined chromosomal rearrangements in mice," Nucl. Acids Res. 27(11):2354-2360 (1999)				

Examiner	Date	
Examinor	Bato	
Signature	Considered	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspx.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**